Q1 2026 is in the books, and the numbers tell the story of an industry in active transformation. Biopharma spent approximately $46.8 billion acquiring 19 companies in three months, with roughly $20 billion in deals announced in the final week alone. That last-day surge—capped by Lilly’s $7.8 billion Centessa deal and Biogen’s $5.6 billion Apellis acquisition on the same Tuesday—sent the XBI up 7% in a single session, turning what was tracking as a negative quarter into a positive one. STAT’s Adam Feuerstein called it “Takeover Tuesday.” Premiums ranged from 38% to 140%. Several pharma companies came back for seconds: Lilly made three acquisitions, Gilead made two, Novartis made two, and GSK doubled up. Jefferies wrote that if deals above $500 million continue at this rate, 2026 could reach $172 billion in total M&A—far exceeding the $111 billion spent across 32 deals in all of 2025. Meanwhile, Immunovant reported that both Phase 3 studies of batoclimab in thyroid eye disease failed their primary endpoint, and orforglipron is 7 days away.
Top Story: Biopharma’s $46.8B Q1 Acquisition Spree Sets the Pace for a Record Year
What Happened: BioSpace published the definitive Q1 M&A tally, reporting that biopharma spent approximately $46.8 billion on acquisitions across 19 deals in the first quarter of 2026. The quarter ended with roughly $20 billion in announced deals in the final week alone. The XBI surged 7% on March 31, rescuing what had been tracking as a negative quarter for the biotech index.
The Deals That Defined Q1
The concentration of deal value in March is striking. The first two months of the quarter were active, but March produced the majority of the quarter’s total value, driven by a cascade of multibillion-dollar transactions that accelerated through the final weeks.
The largest deals of Q1 2026: Gilead/Arcellx at $7.8 billion for CAR-T cell therapy (February). Lilly/Centessa at $7.8 billion for the narcolepsy OX2R agonist pipeline (March). Merck/Terns at $6.74 billion for the allosteric CML inhibitor TERN-701 (March). Biogen/Apellis at $5.6 billion for complement immunology and kidney disease (March). Novartis/Pikavation at $3 billion for the mutant-selective PI3Kα breast cancer inhibitor (March). Lilly/Insilico at $2.75 billion for AI-generated preclinical drug candidates (March). Gilead/Ouro at $2.18 billion for the autoimmune T-cell engager gamgertamig (March). Novartis/Excellergy at $2 billion (March). Sanofi/Kali at $1.23 billion for the trispecific T-cell engager KT501 (March).
Why Pharma Is Spending at This Pace
The strategic imperative driving the M&A wave is no longer theoretical—it is urgent and mathematical. The patent cliff is the common denominator across nearly every major acquirer. Merck faces the loss of Keytruda ($25 billion+ annually) in 2028. Humira erosion continues to pressure AbbVie’s revenue base. BMS faces biosimilar competition across Opdivo and Revlimid. Novartis is building aggressively in oncology and radioligand therapy to sustain growth beyond current franchises.
Internal R&D alone cannot replace the revenue at risk within the timelines these companies face. External innovation, purchased at premium prices, has become the primary growth strategy for big pharma. The willingness to pay premiums ranging from 38% to 140% across the quarter reflects not just the quality of available assets, but the competitive dynamics among buyers who are pursuing the same limited pool of differentiated clinical-stage and commercial-stage programs.
CVR structures appeared in multiple deal architectures as buyers and sellers used contingent payments to bridge valuation gaps. Lilly’s Centessa deal included a $9 per share CVR tied to regulatory approvals. Biogen’s Apellis deal included a $4 per share CVR tied to Syfovre sales milestones. These structures allow buyers to manage risk on early-stage assets while giving sellers credit for upside that has not yet been realized.
The Repeat Buyers
Several companies came back to the M&A table multiple times in Q1, signaling that single acquisitions are not sufficient to address the scale of the pipeline challenges these companies face.
Eli Lilly made three acquisitions: Morphic (GI), Insilico (AI drug discovery), and Centessa (narcolepsy). Combined, Lilly committed more than $11 billion in the quarter to diversify beyond its GLP-1 metabolic core. Gilead made two deals: Arcellx (CAR-T) and Ouro (T-cell engager), totaling approximately $10 billion in commitments to build a two-modality autoimmune franchise. Novartis made two deals totaling $5 billion in oncology. GSK also doubled up during the quarter.
What the Analysts Are Saying About Q2
The consensus is that the pace is not slowing down. Jefferies wrote that if deals above $500 million continue at the Q1 rate, 2026 could reach $172 billion in total M&A—dramatically exceeding the $111 billion spent across 32 deals in all of 2025. BMO identified the companies with the most remaining acquisition capacity: Amgen ($18.6 billion), AbbVie ($33.6 billion), BMS ($21.9 billion), and Novartis ($53 billion). Novartis alone has already made two acquisitions and still has more than $50 billion in capacity.
Revolution Medicines and Viking Therapeutics have been cited by multiple analysts as potential Q2 acquisition targets. The deal pipeline is deep, and the buyers have both the urgency and the balance sheet capacity to continue deploying capital aggressively.
Our Pro brief includes the complete Q1 deal map, a premium analysis showing why 38% to 140% buyout premiums reflect scarcity of quality late-stage assets, and the remaining acquisition capacity for each major pharma company heading into Q2. [Details below.]
What to Watch
The question for Q2 is whether the March surge was driven by end-of-quarter timing pressure or whether it reflects a sustained acceleration in deal activity. AbbVie, BMS, and Amgen have all been conspicuously quiet relative to their acquisition capacity and pipeline needs. If even one of these companies enters the market with a multibillion-dollar deal in Q2, the full-year M&A total could approach the record levels Jefferies is projecting.
The therapeutic areas attracting the most capital tell their own story. Autoimmune and immunology led Q1 deal value, driven by the T-cell engager thesis (Gilead/Ouro, Sanofi/Kali) and complement biology (Biogen/Apellis). Oncology remained the second-largest category with the Merck/Terns CML deal and Novartis/Pikavation breast cancer acquisition. Metabolic and neuroscience deals (Lilly/Centessa, Lilly/Insilico) round out a quarter where capital flowed broadly rather than concentrating in a single therapeutic area. The diversification of deal activity across mechanisms and disease areas suggests the M&A cycle has matured beyond the initial “buy anything in GLP-1” phase into a more disciplined, thesis-driven acquisition environment.
Immunovant’s Batoclimab Misses Primary Endpoint in Both Phase 3 TED Studies
What Happened: Immunovant reported topline results from its two Phase 3 GO clinical studies evaluating batoclimab in active, moderate-to-severe thyroid eye disease (TED). Both studies failed to meet the prespecified primary endpoint of ≥2mm proptosis responder rate at Week 24. The trial design included 12 weeks of high-dose treatment followed by 12 weeks of low-dose treatment. Safety was consistent with prior findings with no new signals identified.
Understanding the Miss
Thyroid eye disease is an autoimmune condition where antibodies targeting the TSH receptor cause inflammation, tissue expansion, and proptosis (bulging of the eyes) in patients with Graves’ disease. Batoclimab is an anti-FcRn antibody designed to lower pathogenic IgG antibody levels, thereby reducing the autoimmune attack on orbital tissue. The mechanism has been validated in other autoimmune conditions—argenx’s Vyvgart (efgartigimod), which also targets FcRn, is approved for myasthenia gravis—but TED presents a different clinical challenge because proptosis involves tissue remodeling that may not fully reverse even when the inflammatory driver is suppressed.
The failure raises an important mechanistic question. Immunovant noted that patients showed greater proptosis improvement during the initial 12-week high-dose period compared to the subsequent 12-week low-dose period. This dose-dependent pattern suggests that sustained deep IgG suppression may be necessary for meaningful clinical outcomes in TED—and that the trial’s step-down dosing design may have undermined the efficacy signal by reducing drug exposure during the critical later treatment phase.
The Pivot: IMVT-1402 and Graves’ Disease
The batoclimab miss is a meaningful setback but not an existential one for Immunovant. The company is pivoting its anti-FcRn strategy to IMVT-1402, a next-generation molecule with a potentially improved pharmacological profile. Registrational data in Graves’ disease is expected in 2027, and a Phase 3 readout in non-infectious uveitis is expected in H2 2026.
The secondary findings from the TED studies support this pivot. Hyperthyroid patients in the GO trials showed thyroid hormone normalization rates similar to Phase 2 data in Graves’ disease—providing mechanistic evidence that anti-FcRn antibodies can effectively modulate the TSH receptor antibody pathway that drives both Graves’ and TED. The failure in TED may reflect the specific clinical challenge of reversing established tissue changes in the orbit rather than a failure of the anti-FcRn mechanism itself.
Roivant, Immunovant’s parent company, held a joint investor call on April 2 to discuss the results and simultaneously announced a new Phase 2b/3 trial of brepocitinib in lichen planopilaris (LPP), an orphan inflammatory scalp disorder affecting approximately 100,000 U.S. adults. The timing of that announcement was clearly designed to offset the batoclimab headlines by demonstrating pipeline breadth—a classic portfolio management move that signals Roivant’s leadership is thinking about narrative management alongside clinical strategy.
The batoclimab miss will likely pressure IMVT shares in the near term, but the broader Roivant ecosystem continues to advance multiple assets across immunology and inflammation. The question for institutional investors is whether the Graves’ disease opportunity for IMVT-1402 is large enough and differentiated enough to sustain Immunovant’s valuation through what could be an 18-month gap before registrational data.
Our Pro brief includes analysis of what the dose-dependent proptosis data means for the broader anti-FcRn class, implications for argenx and UCB’s competing programs, and how the IMVT-1402 pivot in Graves’ disease positions Immunovant for a potential recovery. [Details below.]
What to Watch
IMVT-1402 data in Graves’ disease in 2027 is now the defining catalyst for Immunovant. The H2 2026 non-infectious uveitis readout provides a nearer-term data point that could rebuild confidence in the anti-FcRn approach. The batoclimab dose-response signal—better outcomes at higher doses—may influence trial design for IMVT-1402 and for competing anti-FcRn programs across the industry.
Strategic Themes
1. The Patent Cliff Is No Longer a Future Concern—It Is Actively Reshaping the Industry
$46.8 billion in Q1 M&A is not a cyclical uptick. It is the pharmaceutical industry’s collective response to the most significant wave of patent expirations in its history. Keytruda, Humira, Opdivo, Revlimid—the drugs that built the current generation of large-cap pharma companies are approaching or have already crossed their patent cliffs. The companies that own these franchises cannot replace the revenue through internal R&D on the timelines they face, so they are buying it. The premiums they are paying—up to 140%—reflect both the quality of available assets and the desperation of the timeline. This is not a quarter. It is the beginning of a multi-year M&A supercycle.
2. Repeat Acquisitions Signal That Single Deals Are Not Enough
Lilly made three acquisitions. Gilead made two. Novartis made two. GSK doubled up. The fact that multiple companies returned to the M&A table within the same quarter demonstrates that individual deals are insufficient to address the scale of the pipeline challenge. These companies are assembling portfolios of bets—across mechanisms, therapeutic areas, and modalities—because no single asset can replace a $25 billion franchise. The strategy creates diversification but also creates integration complexity and concentrated binary risk across a growing number of early-stage programs.
3. The Anti-FcRn Class Faces a Clinical Design Reckoning
Immunovant’s batoclimab failure in TED, combined with the dose-dependent efficacy signal, raises important questions for the entire anti-FcRn antibody class. If sustained deep IgG suppression is required for meaningful outcomes in tissue-remodeling autoimmune diseases, trial designs that include dose reductions during the treatment period may systematically underestimate the mechanism’s potential. This has implications not just for Immunovant’s IMVT-1402 but for competing programs from argenx and UCB that are being developed across multiple autoimmune indications with varying tissue involvement.
4. Seven Days Until the Biggest Oral Obesity Decision of the Year
Orforglipron’s April 10 target action date sits at the center of the metabolic landscape. The decision arrives in a quarter that has already produced Wegovy HD’s launch, Novo’s subscription pricing model, retatrutide Phase 3 data, and the Insilico AI drug discovery deal. If approved, orforglipron gives Lilly three distinct metabolic mechanisms on or near the market—a portfolio depth that no competitor can match. The $149 starting price, the $1.5 billion in stockpiled product, and the LillyDirect distribution infrastructure are all in place. Seven days.
Frequently Asked Questions
How much did biopharma spend on M&A in Q1 2026?
Approximately $46.8 billion across 19 deals, according to BioSpace. Roughly $20 billion of that total was announced in the final week of the quarter alone. Jefferies projects that if the pace continues, 2026 could reach $172 billion in total M&A, far exceeding the $111 billion spent in 2025.
Why did the XBI surge 7% on March 31?
The Lilly/Centessa ($7.8B) and Biogen/Apellis ($5.6B) acquisitions were both announced on the same Tuesday, creating a “Takeover Tuesday” that rescued the biotech index from what was tracking as a negative quarter. The M&A announcements signaled that big pharma’s willingness to pay premium prices for biotech assets remains strong.
Which companies have the most M&A capacity left?
BMO identified Novartis ($53 billion), AbbVie ($33.6 billion), BMS ($21.9 billion), and Amgen ($18.6 billion) as the companies with the most remaining acquisition capacity heading into Q2. Novartis has already made two deals and still has more than $50 billion available.
What happened with Immunovant’s TED studies?
Both Phase 3 GO studies of batoclimab in thyroid eye disease failed their primary endpoint of ≥2mm proptosis responder rate at Week 24. The trial used a step-down dosing design (12 weeks high-dose, 12 weeks low-dose), and patients showed better results during the high-dose period, suggesting that sustained deep IgG suppression may be necessary for meaningful TED outcomes. Immunovant is pivoting to its next-generation anti-FcRn antibody IMVT-1402, with registrational Graves’ disease data expected in 2027.
Why does the batoclimab dose-response signal matter for the anti-FcRn class?
The finding that higher-dose treatment produced better proptosis outcomes than the subsequent lower-dose period suggests that trial designs incorporating dose reductions may systematically underestimate anti-FcRn efficacy in tissue-remodeling autoimmune diseases. This has implications for competing programs from argenx and UCB that are being developed across multiple autoimmune indications with varying degrees of tissue involvement.
Which companies are considered potential Q2 acquisition targets?
Multiple analysts have cited Revolution Medicines and Viking Therapeutics as potential targets. The combination of available acquirer capacity (over $125 billion across the top four buyers) and the ongoing patent cliff urgency creates a favorable environment for mid-cap biotech companies with differentiated clinical-stage or commercial assets.
What is the Roivant/brepocitinib announcement?
Roivant announced a new Phase 2b/3 trial of brepocitinib in lichen planopilaris, an orphan inflammatory scalp disorder affecting approximately 100,000 U.S. adults. The announcement was timed alongside the Immunovant batoclimab results to demonstrate pipeline breadth beyond the TED setback.
What should investors focus on with orforglipron 7 days away?
The April 10 target action date is the single biggest near-term catalyst in biopharma. Approval would give Lilly three metabolic mechanisms on or near the market. Key factors include label scope, the $149 LillyDirect starting price, and launch readiness (Lilly has stockpiled $1.5 billion in product). The decision will reshape the competitive terms of the obesity market for the rest of 2026.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Q1 M&A Deep Dive: The Complete Deal Map. We compile every transaction above $500 million, analyze the therapeutic areas and mechanisms attracting the most capital, and identify which companies have the most remaining acquisition capacity heading into Q2. If you’re positioning around the M&A supercycle, this is the definitive reference.
Why Premiums Are Rising: The Scarcity Math. We analyze why buyout premiums ranged from 38% to 140% in Q1, how the shrinking pool of quality late-stage assets is driving competitive bidding dynamics, and what the CVR structures appearing in multiple deals signal about buyer risk tolerance.
Immunovant TED Miss: Anti-FcRn Class Implications. We break down what the dose-dependent proptosis data means for batoclimab’s failure, assess the implications for argenx and UCB’s competing programs, and frame IMVT-1402 in Graves’ disease as the recovery catalyst that determines Immunovant’s trajectory.
Plus: Orforglipron 7-day countdown, Q2 acquisition target candidates, Wegovy HD and subscription model early monitoring, and the updated catalyst calendar through mid-2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
